Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Organon Arixtra Anti-Thrombotic Could Clear FDA By Mid-August

Executive Summary

Organon's anti-thrombotic agent Arixtra could receive approval from FDA in mid-August, Organon President Hans Vemer told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.

You may also be interested in...

Sanofi Steps Up Avapro Support While Bristol Awaits Vanlev And DuPont

Sanofi-Synthelabo is increasing its role in the co-promotion of Avapro ahead of Bristol-Myers Squibb's resubmission of the NDA for Vanlev.

Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III

Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts